Justin Smith
Stock Analyst at Bernstein
(4.32)
# 1,302
Out of 4,495 analysts
166
Total ratings
68.1%
Success rate
11%
Average return
Main Sectors:
Stocks Rated by Justin Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Maintained: Buy | 18,900p | $13,354.00 | +41.53% | 33 | Jul 9, 2026 | |
| LON: GSK GSK plc | Maintained: Buy | 2,630p | $1,959.50 | +34.22% | 23 | Jun 23, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Buy | €915.00 → €877.00 | $807.50 | +8.61% | 11 | May 12, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Sell | kr 175.00 | $320.16 | -45.34% | 2 | May 6, 2026 | |
| SWX: NOVN Novartis AG | Rated: Hold | CHF 125.00 | $124.30 | +0.56% | 1 | Apr 29, 2026 | |
| EPA: SAN Sanofi | Maintained: Buy | €110.00 → €107.00 | $76.48 | +39.91% | 2 | Apr 28, 2026 | |
| SWX: ROP Roche Holding AG | Rated: Buy | CHF 395.00 | $335.50 | +17.73% | 24 | Apr 27, 2026 | |
| NVS Novartis AG | Initiated Coverage: Hold | n/a | $154.62 | - | 1 | Mar 19, 2026 | |
| ETR: MRK Merck KGaA | Initiated Coverage: Hold | €112.00 | $139.60 | -19.77% | 1 | Mar 18, 2026 | |
| LON: 0MGB Genmab A/S | Maintained: Sell | kr 1,015 → kr 1,400 | $1,923.50 | -27.22% | 9 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $29.78 | - | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $24.25 | - | 8 | Aug 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | €10.50 → €2.90 | $1.25 | n/a | 3 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €22.00 → €21.50 | $8.99 | n/a | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $85 → $51 | $57.94 | n/a | 10 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $104 | $125.07 | n/a | 4 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 965.00 → CHF 544.00 | $582.60 | n/a | 8 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | €45.80 → €71.00 | $41.84 | n/a | 7 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €69.00 → €70.00 | $42.22 | n/a | 6 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $52.02 | n/a | 2 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $172 → $140 | $249.91 | n/a | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $52.47 | n/a | 1 | Sep 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $12.13 | n/a | 1 | Nov 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $23.91 | n/a | 1 | Feb 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $78 | $1,216.95 | n/a | 1 | Apr 7, 2016 |
AstraZeneca PLC
Jul 9, 2026
Maintained: Buy
Price Target: 18,900p
Current: $13,354.00
Upside: +41.53%
GSK plc
Jun 23, 2026
Maintained: Buy
Price Target: 2,630p
Current: $1,959.50
Upside: +34.22%
argenx SE
May 12, 2026
Maintained: Buy
Price Target: €915.00 → €877.00
Current: $807.50
Upside: +8.61%
Novo Nordisk A/S
May 6, 2026
Maintained: Sell
Price Target: kr 175.00
Current: $320.16
Upside: -45.34%
Novartis AG
Apr 29, 2026
Rated: Hold
Price Target: CHF 125.00
Current: $124.30
Upside: +0.56%
Sanofi
Apr 28, 2026
Maintained: Buy
Price Target: €110.00 → €107.00
Current: $76.48
Upside: +39.91%
Roche Holding AG
Apr 27, 2026
Rated: Buy
Price Target: CHF 395.00
Current: $335.50
Upside: +17.73%
Novartis AG
Mar 19, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $154.62
Upside: -
Merck KGaA
Mar 18, 2026
Initiated Coverage: Hold
Price Target: €112.00
Current: $139.60
Upside: -19.77%
Genmab A/S
Feb 23, 2026
Maintained: Sell
Price Target: kr 1,015 → kr 1,400
Current: $1,923.50
Upside: -27.22%
Sep 8, 2025
Reiterated: Sell
Price Target: n/a
Current: $29.78
Upside: -
Aug 17, 2025
Maintained: Hold
Price Target: n/a
Current: $24.25
Upside: -
Mar 31, 2025
Downgraded: Hold
Price Target: €10.50 → €2.90
Current: $1.25
Upside: n/a
Dec 10, 2024
Maintained: Buy
Price Target: €22.00 → €21.50
Current: $8.99
Upside: n/a
Mar 11, 2024
Downgraded: Hold
Price Target: $85 → $51
Current: $57.94
Upside: n/a
Mar 11, 2024
Downgraded: Sell
Price Target: $104
Current: $125.07
Upside: n/a
Dec 13, 2023
Maintained: Buy
Price Target: CHF 965.00 → CHF 544.00
Current: $582.60
Upside: n/a
Nov 17, 2023
Upgraded: Buy
Price Target: €45.80 → €71.00
Current: $41.84
Upside: n/a
Nov 17, 2023
Maintained: Buy
Price Target: €69.00 → €70.00
Current: $42.22
Upside: n/a
Feb 27, 2023
Upgraded: Buy
Price Target: n/a
Current: $52.02
Upside: n/a
Nov 8, 2022
Downgraded: Hold
Price Target: $172 → $140
Current: $249.91
Upside: n/a
Sep 3, 2019
Upgraded: Buy
Price Target: n/a
Current: $52.47
Upside: n/a
Nov 12, 2018
Maintained: Buy
Price Target: n/a
Current: $12.13
Upside: n/a
Feb 24, 2017
Downgraded: Hold
Price Target: n/a
Current: $23.91
Upside: n/a
Apr 7, 2016
Initiated Coverage: Hold
Price Target: $78
Current: $1,216.95
Upside: n/a